Controlled study of atenolol in treatment of hypertension.

Hansson, Lennart; Åberg, H; Karlberg, Bengt E.; Westerlund, Anders

doi:10.1136/bmj.2.5967.367

Cited by 66 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28,29] Another explanation for the effect of atenolol could be the limited β-2-blocking potential of atenolol. [30] In the studies used in this overview, the reported side effects and adverse events noted were hypotension, sleep disturbance, constipation, diarrhea, cold extremities and vomiting.…”

Section: Atenololmentioning

confidence: 99%

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Raphaël

Breur

Vlasveld

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited. Areas covered: To evaluate side effects and adverse events of medical treatment in children with infantile hemangioma, a comprehensive review of the literature was performed to provide information for daily practice. In total 254 studies were retrieved from medical databases and comprised 10,022 patients divided into 5 different treatment groups. Information about working mechanism, side effects and adverse events of therapies used as a single agent for IH are discussed and evaluated according to information from pharmacotherapeutic databases. Randomized controlled trials have only scarcely been performed for the many therapeutic options reported for IH. Short-and long-term side effects and adverse events, have not been systematically studied. Subsequently information about the medical treatment options and pharmacotheraputic databases for therapy in children with IH are incomplete. Expert opinion: From the many therapeutic options, propranolol is the first-line approach for IH, predominantly based on clinical observation, efficacy and tolerability in the short-term. The unsolved ravels of possible short and long-term adverse events of propranolol used during early developmental stages of children need thorough review.

show abstract

Section: Atenololmentioning

confidence: 99%

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Raphaël

Breur

Vlasveld

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…Its usefulness in antihypertensive treatment is 0306-5251/82/100107-05 $01.00 well documented (Hansson et al, 1975;Wilcox, 1978).…”

Section: Introductionmentioning

confidence: 99%

Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

Andrén¹,

Karlberg²,

Svensson³

et al. 1982

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol. Twenty-six patients in each group completed the study. 2 Captopril (25-50 mg three times daily) and atenolol (50-100 mg once daily) caused a highly significant fall in blood pressure both supine and standing. 3 When hydrochlorothiazide (25-50 mg once daily) was added a further fall in blood pressure was observed in both groups. 4 Captopril as single drug caused no significant change in heart rate, while atenolol significantly reduced heart rate both supine and standing. 5 Two patients were excluded from the captopril group, one because of a reversible loss of taste and the other because of dizziness. Three patients were excluded from the atenolol group, two because of bradyarrhythmias and one because of inadequate blood pressure response. 6 Both captopril and atenolol were found to be effective antihypertensive agents, suitable for the treatment of essential hypertension.

show abstract

“…without ISA or membrane activity, have been shown to be efFective hypotensive drugs. This has been shown with atenolol (Hansson, Aberg, Karlberg & Westerlund, 1975;LundJohansen, 1976b;Douglas-Jones & Cruickshank, 1976;Zacharias, Cowen, Cuthbertson, Johnson, Prestt, Thompson, Vickers, Simpson & Tuson, 1977;Zacharias, Hayes & Cruickshank, 1977).…”

Section: Group IIImentioning

confidence: 79%

The second Lilly Prize Lecture, University of Newcastle, July 1977. beta‐Adrenergic receptor blockade in hypertension, past, present and future.

Prichard¹

1978

Brit J Clinical Pharma

102

View full text Add to dashboard Cite

All beta‐adrenoceptor blocking drugs that have been described share the common property of being competitive inhibitors. They differ in their associated properties, the presence or absence of cardioselectivity, membrane stabilizing activity, and partial agonist activity. Recently some beta‐adrenoceptor blocking drugs have been reported which also possess alpha‐adrenoceptor blocking activity. The associated properties have been used as a basis for classifying beta‐adrenoceptor blocking drugs (Fitzgerald, 1969, 1972). The presence or absence of cardioselectivity is most useful for dividing beta‐adrenoceptor blocking drugs. The non‐selective drugs (Division I) can be further divided according to the presence or absence of intrinsic sympathomimetic activity (ISA) and membrane stabilizing activity (Fitzgerald's groups I‐IV). Group I possess both membrane activity and ISA, e.g. alprenolol, oxprenolol, group II just membrane action, e.g. propanolol, group III ISA but no membrane action, e.g. pindolol. Fitzgerald placed pindolol in group I but should be placed in group III as it possesses a high degree of beta‐adrenoceptor blocking potency in relation to its membrane activity (Prichard, 1974). Finally drugs in group IV have neither ISA nor membrane action, e.g. sotalol, timolol. The cardioselective drugs (Division II) can be similarly sub‐divided into groups I‐IV according to the presence or absence of ISA or membrane action (Fitzgerald grouped all these together as group V). Lastly there are new beta‐adrenergic receptor blocking drugs which in addition have alpha‐ adrenergic receptor blocking properties (Division III).

show abstract

Controlled study of atenolol in treatment of hypertension.

Cited by 66 publications

References 14 publications

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature

Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

The second Lilly Prize Lecture, University of Newcastle, July 1977. beta‐Adrenergic receptor blockade in hypertension, past, present and future.

Contact Info

Product

Resources

About